CHMP backs use of Celgene's Abraxane in pancreatic cancer
This article was originally published in Scrip
Hot on the heels of FDA approval of Abraxane (paclitaxel protein-bound particles for injectable suspension) in combination with gemcitabine as a first–line treatment for advanced pancreatic cancer (scripintelligence.com, 6 September 2013) experts at the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are recommending the Celgene drug be approved for the same indication in Europe.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.